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REa1. Introduction
Spinal cord injury (SCI) leads to devastating neurological
deficits and disabilities which result in physical and
lifestyle constraints that totally reconfigures daily life.[1,2]
Annually, 12.1–57.8 per million people worldwide are
afflicted with SCI.[3] This condition imposes enormous
psychosocial and financial costs to patients, their relatives,
and the community, representing a significant health
problem associated with the lifelong disability.[1,4] Current
approaches used in the clinical practice to treat this
condition are generally limited to the reduction of pain
and inflammation, through the administration of anti-
inflammatory drugs, aswell as the prevention of secondary
injuries.[5] Until 2009, only six drugs had been tested in
phase III clinical trials: methylprednisolone,[6] naloxone,[7]
tirilazad mesylate,[8,9] monosialoganglioside GM1,[10]
4-aminopyridine,[11] and tizanidine.[12] So far, methylpred-
nisolone has been the only one to have shown some
beneficial effects in acute SCI.[13,14] Other approaches such
as cellular, biomolecular, and biomaterial-based therapies
have been investigated for managing this condition.
However, to date no single repair strategy has successfully
induced full functional recovery following SCI.[1,5] Consid-
ering the complexity of SCI pathophysiologymany experts
agree that the greatest hope for SCI repair will involve a
combinatorial approach that integrates biomaterials, cell
transplantation, and molecule delivery such as that
presented by tissue engineering (TE).[5,15–18] In this field,
three-dimensional porous scaffolds can be used as tempo-
rary extracellular matrix (ECM) that support cellular
adhesion and proliferation by mimicking the in vivo
environment, and thus foster tissue regeneration.[19–22]
Some of the biomaterials used for the production of
scaffolds aimed for SCI applications include collagen,
agarose, alginate, hyaluronic acid, chitosan, fibrin, and
several synthetic polymers such as poly(lactic acid) (PLA),
poly(glycolic acid) (PGA), poly(D,L-lactic acid-co-glycolic acid
(PLGA), and polyethylene glycol (PEG) among others.[23]
Previous studies have shown that limited gliosis,[24,25]
axonal regrowth,[26–28] neuronal regeneration,[29–31] and
some functional recovery after spinal cord transection in
animal models[32–34] can be achieved using several
biomaterial-based scaffolds per se or in combination with
both cellular and biomolecular therapies. However, many
of the studied scaffolds also present drawbacks, such as,
cytotoxicityassociatedwith thegraftedbiomaterial, partial
or total collapse of the grafted structure, and inadequate
degradation rate of the biomaterial in vivo (reviewed by
Madigan et al.[23] and Nomura et al.[35]).
Therefore, there is anurgent need for the development of
scaffolds based on other biomaterials, than those previous-
ly discussed. Thus, in the present study we aimed at
developing a 3D structure for SCI repair based on poly(3-Macromol. Biosci. 2013, DOI: 1
 2013 WILEY-VCH Verlag Gmb
rly View Publication; these are NOT the final paghydroxybutyrate-co-3-hydroxyvalerate) (PHB-HV). The
latter is a copolymer of the bacterial polyester poly(3-
hydroxybutyrate) (PHB), that is accumulated by bacteria as
a carbon and energy storage source.[36] This biomaterial is
found to be particularly attractive for TE applications due
to its properties, such as, optical activity, biodegradability,
biocompatibility, non-toxicity, thermoplasticity, piezoelec-
tricity, and more adjustable properties depending upon
copolymer composition when compared to PHB.[37,38]
Moreover, in vivo, PHB-HV undergoes hydrolytic degrada-
tion producing (R)-3-hydroxybutyric acid[39,40] and 3-
hydroxyvaleric acid—ketone bodies that already exist in
the blood under normal physiological conditions—not
known to lead to long term tissue reactions at the
implantation site.[39–41] Furthermore, Chen and Tong[42]
have recently reported the ability of PHB-HV-based micro-
spheres to support a variety of neuronal cell types and
promote greater axon-dendrite segregation.
In this report,weaddress themorphological,mechanical,
and biological characterization of PHB-HV-based 3D scaf-
folds aimed for SCI regeneration. For this purpose, PHB-HV
3D scaffolds produced by freeze-drying were characterized
and its suitability for the treatment of SCI was assessed
through cytotoxicity evaluation and direct contact assays
performed with different cell populations relevant for SCI
regeneration. Moreover, in vivo histocompatibility assays
in a subcutaneousmodel and locomotor function recovery,
in a hemisection rat model of SCI, were also performed.2. Experimental Section
2.1. PHB-HV 3D Scaffolds Preparation and
Characterization
PHB-HV 3D scaffolds were produced through an emulsion
freezing/freeze-drying technique described by Sultana and
Wang.[39] 7.5% (m/v) PHB-HV (12% HV content) polymer
powder with a molecular weight of approximately 425.692 kDa
(PHB Industrial, Brazil), chloroform (w¼0.5) (VWR International–
Laboratorial Material Ltd., Portugal) and acetic acid (w¼ 0.5)
(Panreac, Spain) were used for the emulsion preparation.
Briefly, PHB-HV powder was dissolved in chloroform at 65 8C,
under constant magnetic stirring. After obtaining a homogeneous
polymer solution, acetic acid (1:1)wasaddedand the emulsionwas
stored overnight at80 8C. Subsequently, the frozen emulsionwas
lyophilized (Telstar, Spain) at80 8C for 94h. By adding acetic acid
(water phase), two immiscible phases are created, where the
continuous phase contains the polymer-rich solvent and the
dispersed phase iswater.With this approach it is possible to have a
better control over porosity and pore size than just freeze-drying
thepolymer solution. The scaffoldsproducedwere stored in ahotte
at room temperature to promote the evaporation of any residual
solvent until being cut in smaller cylindrical pieces of 4mm in
diameter and 5mm in height and sterilized through the action of
ethylene oxide (Pronefro, Portugal).0.1002/mabi.201300178
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Scanning electron microscopy (SEM) was used to study the
morphology/interconnectivityof theporeswithin the3Dstructure
of the PHB-HV scaffolds. For this purpose, all samples were coated
with Au/Pd through ion-sputtering before observation in a
Stereoscan 360 scanning electron microscope (Leica Cambridge
Co., United Kingdom).
2.1.2. Micro-Computed Tomography (m-CT) Assessment
The general architecture, porosity and pore size of the scaffolds
was assessed by m-CT (SkyScan 1072, Belgium), using a high
resolution mode of 6.9mm x/y/z and an exposure time of
1792ms. The energy parameters defined in the scanner were
50 kV and 185mA. Afterward, the obtained data was processed
using NRecon, CT-An, and CT-Vol image software’s (Sky Scan,
Belgium) for m-CT reconstruction, analysis, and visualization
of the 3D scaffold representation. Then, to determine the
percentage of porosity and average pore size, a volume of interest
(VOI) consisting of 300 layers with a circular region of interest
(ROI) with ﬃ4mm diameter was selected for each scaffold. A
threshold (to distinguish polymeric material from pore voids)
of 60–255 was chosen and maintained constant for all the
scanned specimens.
2.1.3. Compressive Mechanical Properties Evaluation
Mechanical performance of the developed scaffolds was assessed
through compression testing using an universal mechanical
testing equipment (Instron 5540, United Kingdom) at a cross-head
speed of 2mmmin1, under both dry and wet (after a 3h
incubation period in phosphate buffer saline 0.1M, pH 7.2 at
37 8C) conditions. Seven replicates were conducted. For both cases,
the compressive modulus was determined on the most linear part
of the stress–strain curve.2.2. In Vitro Cytotoxicity Evaluation
Short-term cytotoxicity of the developed scaffolds was assessed as
previous described by Salgado et al.[43] For this purpose minimum
essentialmedium (MEM) extraction andMTS testswere performed
with a 1, 7, 14, 21, and 28d of extraction. TheMEMextraction test is
aimed to evaluate changes in cell morphology and growth
inhibition, whereas the MTS test establishes whether cells are
metabolically active.[44,45]
In all tests performed, latex rubber (Kimberly-Clark, USA) and
standardculturemedium(formulationdescribedbelow)wereused
as negative and positive controls for cell viability, respectively.
After each period the extracts were collected and filtered through
a 0.20mm-pore-size filter. These assays allow the assessment of
the possible toxic effect of the leachables released from the
biopolymers during the extraction.
2.2.1. In Vitro Cell Culture
For the in vitro cytotoxicity evaluation a mix primary culture of
neurons and astrocytes from the hippocampus of P4 Wistar
rats (Charles River Laboratories, Barcelona, Spain) were used.Macromol. Biosci. 2013, DOI:
 2013 WILEY-VCH Verlag Gmwww.MaterialsViews.com
Early View Publication; these are NOHippocampus derived primary cell cultures were allowed to grow
in Neurobasal-A (Invitrogen, USA) supplemented with 2% B27
(Invitrogen, USA), 0.25% bFGF (Gibco, USA), 0.5% Glutamax
(Invitrogen, USA), and 1% Kanamycin (Invitrogen, USA), at 37 8C
in a humidified atmospherewith 5%v/v CO2, for 5 d. Cultureswere
then incubatedwith1mLwell1 of extractionfluid for 72hat37 8C,
in a 5% v/v CO2 humidified atmosphere.
2.2.2. MEM Extraction Test
Seventy-two hours after culture in extraction fluid, an immunocy-
tochemistryprocedurewas conducted. The immunocytochemichal
staining with mouse anti-rat microtubule associated protein
2 (MAP2) (Sigma, MO, USA) and rabbit anti-rat glial fibrillary acid
protein (GFAP) (Dako, Denmark) antibodies was performed
according to the protocol described by Salgado et al.[46] Upon
staining, cultures were observed under a fluorescence microscope
(Olympus BX-61, Germany) and images were captured by a digital
camera (DP70, Olympus Corporation, Germany).
2.2.3. MTS Test
Cellsmetabolic viability after exposure to the extraction fluidswas
assessed using the substrate [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2(4-sulfophenyl)-2H tetrazolium] (MTS;
CellTiter96AQueousOneSolutionCell ProliferationAssay; Promega,
USA) which is reduced into a brown formazan product by
dehydrogenases enzymesactive in allmetabolically viable cells.[45]
The extraction procedure was conducted as follows. After 72h of
incubation, the extraction fluidswere replaced for 500mLwell1 of
neurobasal-amediumcontainingMTS, in a 5:1 ratio. Cultureswere
then incubated for 3 h in a humidified atmosphere at 37 8C and
5% v/v CO2. Following this period, triplicates of 100mL of
solution from each sample were transferred to 96-well plates
and the optical density (O.D.) was measured at 490nm using a
multi-well plate reader (Bio-Rad, USA).2.3. Direct Contact Assays
Before seeding, PHB-HV scaffolds were coated with poly-D-lysine
(PDL; Sigma, MO, USA) and incubated in culture medium at 37 8C
and 5%v/vCO2 for 3 h to allow culturemediumuptake. Several cell
populations were used to conduct direct contact assays with PHB-
HV scaffolds.
Primary Cultures of Hippocampus Derived Cells: As previously
referred hippocampus derived primary cell cultureswere prepared
fromP4Wistar rats.Briefly,afterbraindissection,hippocampiwere
submitted to a 2.5% trypsin based enzymatic digestion and
subsequent mechanical dissociation.[46] Upon isolation cells were
seeded into the scaffolds at a density of 2105 cells per scaffold
(n¼ 5). Two-hours after static seeding the cells/scaffold constructs
were incubated in culture medium (formulation described in
Section 2.2.1.) for 48h, 7 and 14 d, at 37 8C and 5% v/v CO2. The
culture medium was routinely replaced every 2–3 d until the end
of the experiment.
Primary Cultures of Cortical Glial Cells: Cortical glial cells were
isolated from newborn Wistar rats (P4). After dissection, cortices
were enzymatically digested (30UmL1 DNAse, 0.25% Trypsin,
both from Sigma, MO, USA) followed by mechanical10.1002/mabi.201300178
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REadissociation.[46] Upon isolation, cortical glial cells were seeded
into the scaffolds at a density of 2105 cells per scaffold (n¼4).
Then the cells/scaffold constructs were incubated in culture
medium (DMEM, Sigma, MO, USA; 10% FBS, Invitrogen, USA; 1%
antibiotic–antimycotic mixture, Sigma, MO, USA) for 48h, 7 and
14 d, at 37 8C and 5% v/v CO2. The culture medium was routinely
replaced every 2–3 d until the end of the experiment.
Human Umbilical Cord Perivascular Cells (HUCPVCs): HUCPVCs
were isolatedaccording to theproceduresdescribedbySarugaseret
al.[47] and cultured as monolayers in AlphaMEM (Invitrogen, USA)
medium supplemented with 10% FBS and 1% antibiotic–anti-
mycoticmixture.Uponconfluency, cellsatpassage4weredetached
and seeded into the scaffolds as previously described for
hippocampus and glia cultures, at a density of 5104 cells per
scaffold (n¼ 3). Subsequently, cells/scaffold constructs were
incubated in culture medium (formulation described above) for
48 h and 7 d, at 37 8C and 5% v/v CO2. The culture medium was
routinely replaced every 2–3 d until the end of the experiment.
BoneMarrowDerivedMesenchymal StromalCells (BM-MSCs): BM-
MSCs, acquired from Lonza (Switzerland), were cultured as
monolayers in Alpha MEM medium supplemented with 10% FBS
and 1% antibiotic–antimycotic mixture, in sterile T175 tissue
culture flasks. Upon confluency, cells at passage 4 were detached
andseeded into thescaffoldsatadensityof5 104cellsper scaffold
(n¼3) and submitted to the same culture conditions described for
HUCPVCs.
Adipose-Derived Adult Stem Cells (ASCs): ASCs isolated according
to the protocol described by Gimble and Guilak,[48] were cultured
asmonolayers inAlphaMEMmediumsupplementedwith10%FBS
and 1% antibiotic-antimycotic mixture, in sterile T175 tissue
culture flasks. Again, upon confluency, cells at passage 4 were
detached and seeded into the scaffolds at a density of 5 104 cells
scaffold (n¼ 3) and maintained in culture as described for
HUCPVCs.
Olfactory Ensheathing Cells (OECs): Olfactory ensheathing cells
were isolated from the olfactory bulbs of newbornWistar rats (P4)
and cultured as previously described.[49] Briefly, after dissection,
the olfactory bulb tissue was enzymatically digested (0.125%
Collagenase type I, 50UmL1 DNAse, both from Sigma, MO, USA)
followed by mechanical dissociation. After isolation, the cell
suspension was transferred to uncoated 6-well plates and
incubated for 54 h at 37 8C and 5% v/v CO2, in order to allow the
attachment of both fibroblasts and astrocytes. Subsequently, OECs
were cultured in DMEM/F12 medium (Invitrogen, USA) supple-
mented with 2% FBS, 1% antibiotic-antimycotic mixture, 0.04%
Bovine Pituitary Extract (BPE, Gibco, USA), 0.008% Forskolin (Fsk,
Sigma, MO, USA) and 0.25% bFGF. Upon approximately 90%
confluence, cells at passage 1were then harvested and seeded into
thescaffoldsasdescribedbefore,atadensityof2 105cells scaffold
(n¼4). Afterwards, cells/scaffold constructs were incubated in
culturemedium (formulation described above) for 48h, 7 and 14 d,
at 37 8C and 5% v/v CO2. The culture medium was routinely
replaced every 3–4 d until the end of the experiment.
2.3.1. Cell Metabolic Viability Assessment by MTS Assay
After each culture period, cell metabolic viability was assessed
using the MTS test. The cells/scaffold constructs were
transferred to new 24-well plates and immersed in a mixtureMacromol. Biosci. 2013, DOI: 1
 2013 WILEY-VCH Verlag Gmb
rly View Publication; these are NOT the final pagcontaining serum-free cell culture medium and MTS reagent in
a 5:1 ratio. The procedure was then carried out as described
in Section 2.2.3.
2.3.2. Cell Proliferation Assays
Cell proliferation was assessed using ELISA BrdU colorimetric test
(Roche, USA) which allows the assessment of cell proliferation
within a 24h period and a fluorimetric double-stranded DNA
(dsDNA) quantification kit (PicoGreen, Molecular Probes, USA) for
the ascertainment of the overall cell proliferation throughout the
experimental time points. Both tests were executed according to
manufacturer’s instructions.
For the ELISA BrdU test, the cells/scaffold constructs were
incubatedwith 10mM BrdU for 24h prior to the completion of each
time point, after which they were immersed in FixDenat solution
(Roche, USA). Subsequently, the constructs were incubated in a
solution containing Anti-BrdU-POD reagent (Roche, USA) for 1 h
and a half. After this, the constructs were rinsed three times with
PBS 0.1M pH 7.2 and incubated with TMB reagent (Roche, USA) for
15min. The reactionproductwas thenquantifiedbymeasuring the
absorbance at 370nm against a reference wavelength of 492nm
using an ELISA plate reader (Bio-Rad, USA).
To determine the total amount of dsDNA a fluorimetric dsDNA
quantification kitwas used. Sampleswere collected at each culture
period rinsed three timeswith PBS0.1MpH7.2 and transferred into
microtubes containing 1mL of ultrapure water. The cells/scaffold
constructs were then stored at 80 8C for further analysis. Prior to
DNA quantification, samples were thawed and sonicated for
15min. Standards were prepared with concentrations ranging
between0and2mgmL1.Afterwardsampleor standard,PicoGreen
solution and Tris-HCl-EDTA buffer were added to each well of an
opaque 96-well plate (Costar, USA) and incubated in the dark for
10min. Following this period the fluorescence was measured
using an excitation wavelength of 480nm and an emission
wavelength of 520nm.
2.3.3. Cells Distribution within the PHB-HV Scaffolds
CNS-derived cells distribution within the scaffolds was assessed
through immunocytochemistry performed after each culture
period according to the protocol described by Salgado et al.[46]
For this purpose the following antibodies were used: mouse anti-
rat MAP2 to detect mature neurons; rabbit anti-rat GFAP to detect
astrocytes; mouse anti-rat O4 (RD System, USA) for detection of
oligodendrocytes; and mouse anti-rat CD11b (BD Pharmingen,
USA) for detection of microglia.
The distribution of HUCPVCs, BM-MSCs, ASCs, and OECs within
the scaffolds was evaluated using a combination of phalloidin
(Sigma,MO,USA)andDAPI (Sigma,MO,USA). For thispurpose,after
each culture period the cells/scaffold constructs were rinsed three
times with PBS 0.1M pH 7.2, and incubatedwith 4% paraformalde-
hyde (PFA;Merck, Germany) for 45min. Subsequently, the samples
were incubated with phalloidin during 45min followed by the
incubation with DAPI for 10min. Throughout the several steps of
the staining procedure the cells/scaffold constructs were washed
with PBS 0.1M pH 7.2.
Upon staining, the samples were cut in half (2mm depth) and
both the inner and the outer surface observed under a confocal0.1002/mabi.201300178
H & Co. KGaA, Weinheim www.MaterialsViews.com
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Germany).
All the former described experiments were performed twice to
guarantee the reproducibility of the obtained results.2.4. In Vivo Histocompatibility Evaluation
2.4.1. Subcutaneous Implantation
Wistar rats were purchased from Charles River. Animals were
housed in pairs under standard conditions of light, temperature,
and humidity. Water and food (standard diet.) ad libitum. The
maintenance andmanipulation of the animalswere in accordance
with the Federation of European Laboratory Animal Sciences
Associations Directive 2010/63/EU. A mixture of ketamine
(Imalgene—75mgkg1; Merial, Portugal) and medetomidine
(Dorbene Vet—0.5mgkg1; Esteve Veterinaria, Portugal) was used
to anesthetize the rats. Once anaesthetized, four incisions per
animalwereperformed(reachingamaximumof1.5 cmeach)being
two in the interscapular region and the other two in the lumbar
region. With the help of a forceps one side pocket was created
througheachof the incisionsandPHB-HVscaffoldswere implanted
subcutaneously in a total of nine animals. Four scaffolds were
implanted per animal, being two on the anterior region and other
two on the posterior region. The incision sites were sutured and
upon recovery from anesthesia the rats were returned to their
respective compartments and kept under food and drink ad
libitum. The subcutaneous implants weremaintained for 1, 4, and
12 weeks (three animals/time point). At the end of each time
point, sodium pentobarbital (Eutasil—150mg  kg1; Ceva Saude
Animal, Portugal) was intraperitoneally injected to euthanize the
animals. The scaffolds were removed, fixed in 3.7% formaldehyde
(Labsolve—JMGS Lda., Portugal), processed for paraffin type 6
(Richard-Allan Scientific, USA) embedding, and stained with
hematoxylin–eosin (H&E, Leica Auto Stainer XL, United Kingdom).
2.4.2. Hemisection Rat Model of SCI
A total of 8 Wistar rats (Charles River) were anesthetized by
intraperitoneal injection of a mixture of ketamine (Imalgene:75
mgkg1; Merial, Portugal) and medetomidine (Dorbene Vet:
0.5mgkg1; Esteve Veterinaria, Portugal). Once anaesthetized,
furwas shaved from the surgical site and the skin disinfectedwith
chlorohexidine (AGB). Then a dorsal midline incision was made
from T6–T11 and the paravertebral muscles retracted. A laminec-
tomy was performed at the junction T8–T9 in which the spinous
processes were removed and the spinal cord exposed. Two
hemisections were performed on the left side 3mm apart of each
other and the tissue in between removed. After SCI, PHB-HV
scaffolds were implanted in the injury site followed by the
implantation of a 3D semi-tubular starch/polycaprolactone (SPCL)
scaffolds at the vertebral bone level, juxtaposed to the spinal cord
providing spine stabilization, as previously described by Silva et
al.[50] Bone cement (Biomet, USA)was used to fix the SPCL scaffolds
margins to bone. After scaffolds implantation, paravertebral
muscles and skin were separately closed with Vicryl sutures
(Johnson and Johnson, USA). Animals were divided into twoMacromol. Biosci. 2013, DOI:
 2013 WILEY-VCH Verlag Gmwww.MaterialsViews.com
Early View Publication; these are NOexperimental groups: animals with spine stabilization (control,
n¼4), and animals with PHB-HV scaffold implantation and spine
stabilization (PHB-HV, n¼ 4). Handling was performed for 3 d
before the surgery.
Following SCI surgery rats were kept under heat lamps and
received vitamins (Duphalyte—1mLkg1 d1, Farmoquil—Socie-
dade Farmo-quımica, Lda., Portugal), analgesic (Butorphanol
tartrate—5mgkg1 d1, Plurivet—Veterinaria e Pecuaria, Lda.,
Portugal), antibiotic (Enrofloxacine—5mgkg1 d1, Bayer
Portugal, S.A., Portugal) and saline solution (NaCl0.9%—10mLkg1
d1, Ultimedica, Portugal), daily for the first 72h. Bladder
evacuation was done manually. Throughout the treatment and
recoveryperiod, animalswere examined for symptomsof illness or
potential reaction to the treatment.
2.4.2.1. Assessment of Locomotor Function by BBB Test
All rats were assessed with the Basso, Beattie, Bresnahan
Locomotor Rating Scale (BBB)[51] on weeks 1, 2, 3, and 4 after
injury. The BBB is a 21-point scale designed to assess hindlimb
locomotor function recovery following SCI. A BBB score of
0 indicates no spontaneous hindlimb movement. A BBB score of
1 through 8 indicates isolated joint movements, but no weight
support. A BBB score of 9 through 20 indicates an ability to support
weight and use the limb for locomotion but with some degree of
abnormality. A BBB score of 21 corresponds to the normal
locomotion pattern of a rat.
2.4.2.2. Tissue Preparation
Four weeks after scaffolds implantation the rats were deeply
anesthetized through an intraperitoneal injection of sodium
pentobarbital (Eutasil: 150mgkg1; Ceva Saude Animal, Portugal).
Next, the animalswere perfused through the ascending aortawith
4% PFA in PBS 0.1M pH 7.2. A 2.5–3 cm length of spine, centered on
the site of hemisection and scaffold placement, was carefully
removed and fixed in neutral buffered formalin (Labsolve, JMGS
Lda., Portugal).Afterfixation, the spineswereprocessed forparaffin
type 6 (Richard-Allan Scientific, USA) embedding, and stainedwith
H&E (Leica Auto Stainer XL, United Kingdom). The tissue was
sectioned on the coronal plane and tissue infiltration/organization
was evaluated on slices of the median cord subdivision.2.5. Statistical Analysis
Statistical analysis was performed using GraphPad Prim 5.00
software for Windows (GraphPad Software, San Diego, USA).
Statistical evaluationwasperformedusing theone-wayanalysisof
variance (ANOVA)test followedbytheTukeyposthoctest, toassess
the statistical differences regarding cell viability and proliferation
inside the scaffolds between the different cell culture periods.
Evaluationof statisticaldifferences concerning invitro cytotoxicity
assays, cell viability and proliferation inside the scaffolds between
the different types of mesenchymal-like stem cells studied, and in
vivo locomotor function assessment was scrutinized through a
two-way ANOVA test followed by a Bonferroni post hoc test.
Statistical significant values were defined for p<0.05.10.1002/mabi.201300178
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REa3. Results
3.1. PHB-HV Scaffolds Characterization
The 7.5% (m/v) PHB-HV scaffolds produced by freeze-
drying technique revealed a cross macro-structure pre-
senting organized laminar porous (Figure 1a–c), while
its longitudinal macro-structure exhibited round pores
(Figure 1d–f). The scaffolds were analyzed by microCT for
morphometric analysis and 3D reconstruction (Figure 2).
These analyses revealed that PHB-HV scaffolds possess
an average pore size of 163.5 0.1mm and a porosity of
88.1 0.3%.
The compressivemechanical tests revealed that PHB-HV
scaffolds exhibit an anisotropic behavior, with a compres-
sivemodulus of 1.4 0.7MPa on the longitudinal direction
(Table 1) and a compressive modulus of 2.9 0.3MPa on
the cross-section direction (Table 1). Such evidence is in
accordancewith theanisotropic featuresof these structures
unveiled by the SEM analysis results. Moreover, it was
also possible to observe that after 3h incubation the
compressive modulus of these structures had decreased
approximately 50% on the longitudinal direction and
approximately 69% on the cross-section direction (Table 1).3.2. In Vitro Cytotoxicity Evaluation of PHB-HV
Scaffolds
The cytotoxicity of PHB-HV scaffolds was assessed
using hippocampus derived primary cell cultures to
ascertain the effect of PHB-HV degradation productsFigure 1. Representative SEM images of the macro-structure of PHB-
technique. A) Cross-section of the scaffolds magnified; B) 100
200mm;C) 200 (enlarged view of a region in the middle of t
the scaffolds magnified; E) 100 (porous structure in the middle o
view of a region in the middle of the longitudinal section), scale ba
disclosing both round and laminar pores.
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extraction test associated with immunocytochemistry
staining (Figure 3a) revealed that cells density and
morphologywere very similar between the cells incubated
in PHB-HV extracts, collected at different time points, and
the cells grown inNeurobasal-Amedium (positive control),
contrasting the notorious absence of viable neurons
observed in cells grown in Neurobasal-A medium contain-
ing latex leachables (negative control). The immunocyto-
chemistry staining evidences were further confirmed by
the MTS test (Figure 3b), under which cells produced large
amounts of a brown formazan product after incubation
with both Neurobasal-A medium and the scaffolds’
extracts. This is an indicator of metabolic viability as cells
incubated with some of the degradation products of
the PHB-HV scaffolds were able to incorporate and
metabolize MTS.3.3. Interaction between CNS-derived Cells and
PHB-HV Scaffolds
Since the aim of this work was to investigate the
therapeutic potential of PHB-HV based-scaffolds for SCI
regeneration, the interaction between primary cultures of
CNS-derived cells (primary cultures of both hippocampal
and cortical glial cells) and the developed scaffolds was
studied. For this purpose cell morphology, metabolic
viability, and proliferation were assessed by immunocyto-
chemistry, MTS test and, ELISA BrdU test and dsDNA
quantification, respectively.HV 3D scaffolds produced through emulsion freezing/freeze-drying
(porous structure in the middle of the cross-section), scale bar:
he cross-section), scale bar: 200mm. D) Longitudinal section of
f the longitudinal section), scale bar: 200mm; F) 200 (enlarged
r: 200mm. PHB-HV 3D scaffolds exhibit an anisotropic morphology
0.1002/mabi.201300178
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Figure 2. Representative A) 2D and B) 3D micro-CT images
of PHB-HV 3D scaffolds produced through emulsion freezing/
freeze-drying technique. These scaffolds display a fully
interconnected network of pores with arbitrary shapes, sizes,
and directions.
Table 1. Compressive mechanical properties of PHB-HV 3D
scaffolds.
Direction Condition
Compressive
modulus
[MPa]
Longitudinal Dry 1.4 0.7
Wet 0.7 0.2
Cross-section Dry 2.9 0.3
Wet 0.9 0.3
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cell cultures demonstrated that these cells were able to
adhere, to maintain their viability and to proliferate
throughout the scaffolds structure (Figure 4a–c). BrdU
data showed a progressive decrease in the amount of
proliferatingcellswith time (Figure4d)alongwithan initialMacromol. Biosci. 2013, DOI:
 2013 WILEY-VCH Verlag Gmwww.MaterialsViews.com
Early View Publication; these are NOslight increase of the total dsDNA present in the scaffolds
between days 2 and 7, followed by its statistically
significant decrease (p< 0.001) between days 7 and 14
(Figure 4e). Moreover, the MTS test results revealed a
progressive increase in the metabolic activity of these
cells (Figure 4f).
Primary cultures of cortical glial cells showed that
astrocytes and oligodendrocytes were also able to adhere,
maintain their viability and proliferate within the
scaffolds structure (Figure 5a–i). Throughout the experi-
ment period, a progressive decrease in the amount of
proliferating cells with time was registered (Figure 5j)
regardless of the gradual increase in both the total dsDNA
content of the scaffolds (Figure 5k) and cells metabolic
activity (Figure 5l).3.4. Interaction between Mesenchymal-like Stem
Cells and PHB-HV Scaffolds
All the three distinct types of mesenchymal-like stem cells
(MSCs) (HUCPVCs, BM-MSCs, and ASCs) studied demon-
strated ability to adhere, to maintain their viability and to
proliferate within the scaffolds structure (Figure 6a–d) as
previously observed with the CNS-derived cells. All MSCs
showed increases in the amount of proliferating cells with
time (Figure 6e), in the total dsDNA content within the
scaffolds (Figure 6f) and in their metabolic activity
(Figure 6g).
Moreover, the comparison between the interactions
of the three different types of MSCs with the scaffolds
revealed that HUCPVCs presented the greatest increase in
total dsDNA (Figure 6f) as already observed in the second
day of culture (Figure 6e). However, the greatest increase
regarding the metabolic viability was registered for ASCs
(Figure 6g).3.5. Interaction between OECs and PHB-HV Scaffolds
The study of the interaction between OECs and the
scaffolds showed that these cells, like the other cell types10.1002/mabi.201300178
bH & Co. KGaA, Weinheim 7
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Figure 3. In vitro cytotoxicity evaluation results. Hippocampus derived primary cell cultures after a 72 h incubation period with extracts
containing standard culture medium (positive control for cell viability), latex rubber plus standard culture medium (negative control
for cell viability) and PHB-HV scaffolds plus standard culture medium (PHB-HV extract), collected after 1, 7, 14, 21, and 28 d of extraction.
A) Representative fluorescence images showing similar cells densities and morphology between cells grown in the extracts corresponding
to positive control and PHB-HV extract, contrasting the results observed for cells grown in negative control extract. Nucleus stained
in blue (DAPI), astrocytes stained in green (GFAP) and neurons (some indicated by the arrows) stained in red (MAP2). The scale bar
indicates 20.0mm. B) MTS test results demonstrating that cells grown in positive control and PHB-HV extracts were able to metabolize
MTS in greater extent than cells grown in negative control extract. O.D. read at 490nm. (p<0.01, p<0.001; two-way ANOVA,
n¼ 5, mean SD).
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proliferate within the scaffolds structure (Figure 7a–c).
However, although the ELISA BrdU data demonstrated a
significant increase in the amount of proliferating cells
between days 2 and 7 (Figure 7d), this was not verified by
the dsDNA quantification assay (Figure 7e) which showed
a maintenance of the total dsDNA content within the
scaffolds. Concerning the metabolic viability assays, the
results obtained revealed that these cells maintained their
metabolic viability throughout the experiment with a
small, but significant, increase between days 7 and 14
(Figure 7f).Macromol. Biosci. 2013, DOI: 1
 2013 WILEY-VCH Verlag Gmb
rly View Publication; these are NOT the final pag3.6. In Vivo Histocompatibility Evaluation
3.6.1. Subcutaneous Implantation
The scaffolds integration into the host tissue analyzed by
H&E staining revealed that the scaffolds evoked an initial
inflammatory response along with the deposition of some
collagen fibers in the interface between the scaffold and
the adjacent tissue detected after 1 week of implantation
(Figure 8a,b). After the fourth week of implantation the
initial inflammatory response faded (Figure8c,d) and itwas
possible to detect the presence of blood vessels containing0.1002/mabi.201300178
H & Co. KGaA, Weinheim www.MaterialsViews.com
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Figure 4. Direct contact assays with hippocampus derived primary cell cultures results. Cells were seeded (200000 cells per scaffold) and
grown up to 14 d. Representative fluorescence images showing a central area of scaffolds seeded with hippocampus derived primary cell
cultures evidencing that these cells were able to adhere, maintain their viability and proliferate throughout the scaffolds structure after
A) 2 d, B) 7 d, and C) 14 d in culture. Nucleus stained in blue (DAPI), astrocytes stained in green (GFAP) and neurons stained in red (MAP2). The
scale bar indicates 100mm. D) ELISA BrdU data demonstrating a progressive decrease in the amount of proliferating cells over time.
O.D. read at 370nm/492nm. E) Total dsDNA quantification data revealing a non-statistically significant increase on dsDNA content
between days 2 and 7, followed by its significant decrease between days 7 and 14. F) MTS test results showing a progressive increase in cells
metabolic activity over time. O.D. read at 490nm. (p<0.01, p<0.001; one-way ANOVA, n¼ 5, mean SD).
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connective tissue throughout the scaffolds structure and
some scattered areas containing a few macrophages
(Figure8d, somemacrophages indicatedbytheblackarrows).
Moreover, there was no evidence of necrotic tissue and it
was possible to observe some scaffold degradation when
compared to the data obtained for week 1 (Figure 8a–d).
Twelve weeks after implantation it was possible to
observe an increase in the amount of connective tissue
contained inside the scaffolds and the presence of blood
vessels. At this time point it was also possible to observe
that PHB-HV scaffolds degradation occurred along with
an apparent reduction of the scaffolds structure volume.
A thin capsule of connective tissue surrounding the
scaffolds had meanwhile disappeared and, as for the other
time points, there was still no evidence of necrotic tissue
(Figure 8e,f).3.6.2. Hemisection Rat Model of SCI
The effects of scaffolds integration into the damaged
spinal cord tissue was scrutinized by locomotor functionMacromol. Biosci. 2013, DOI:
 2013 WILEY-VCH Verlag Gmwww.MaterialsViews.com
Early View Publication; these are NOevaluation and histological characterization. The left
hindlimbmotor function evaluation began onweek 1 after
surgery and continued weekly for 1 month. The identity
of the animals was kept blind to the observer in all the
experiments.
The BBB test data revealed no statistical significant
differences between the left hindlimb function of control
and PHB-HV groups throughout the testing period
(Figure 9a). Four weeks after surgery animals from both
experimental groups were able to extensively move at
least two joints of the left hindlimb (3.75 1.5 in the
BBB score). This observation suggests that the presence
of the PHB-HV scaffolds did not lead to either an
improvement or worsening of the left hindlimb motor
function recovery.
Hematoxylin and eosin (H&E) staining was performed
to assess the effects of PHB-HV scaffolds implantation on
the spinal cord tissue organization, surrounding tissue
infiltration, and axon vacuolization after SCI. The analyses
of coronal median cord sections showed that 4 weeks after
surgery the tissues in which PHB-HV scaffold had been
implanted (Figure 9c) presented higher quantity of cells on10.1002/mabi.201300178
bH & Co. KGaA, Weinheim 9
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Figure 5. Direct contact assays with primary cultures of cortical glial cells results. Cells were seeded (200 000 cells per scaffold) and grown
up to 14 d. Representative fluorescence images presenting a central area of scaffolds seeded with primary cultures of cortical glial cells
revealing that these cells were also able to adhere, maintain their viability and proliferate throughout the scaffolds structure over time.
Astrocytes stained in green (GFAP) after A) 2 d, B) 7 d, and C) 14 d in culture. Oligodendrocytes stained in red (O4) after a D) 2 d, E) 7 d, and
F) 14 d in culture. Microglia cells stained in red (CD11b) after a G) 2 d, H) 7 d, and I) 14 d in culture. Nucleus stained in blue (DAPI). The
scale bar indicates 100mm. J) ELISA BrdU data showing a progressive decrease in the amount of proliferating cells over time. O.D. read at
370nm/492nm. K) Total dsDNA quantification data revealing a non-statistically significant increase on dsDNA content between days 2
and 7, followed by its significant decrease between days 7 and 14. L) MTS test results demonstrating a progressive increase in cells
metabolic activity over time. O.D. read at 490nm. (p<0.05, p<0.01, p<0.001; one-way ANOVA, n¼4, mean SD).
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Moreover, it was possible to detect the presence of blood
vessels and collagen fibers with some degree of alignment
in some peripheral areas of the scaffold. Additionally,
occurrence of vacuolization on the left side of the cord
compared to the right side was observed. Neutrophils and
macrophages were detected. Moreover, there was also
evidence of some fibrosis in the scaffolds peripheral area
subjacent to the vertebral cord. Finally, no necrotic tissue
was observed.
The same analyses performed in coronal median cord
sections of the control group (Figure 9b) revealed some
inflammation in the vicinity of the lesion along with few
fibrosis and the presence of blood vessels. There was also
evidence of vacuolization; however, this seemed to beMacromol. Biosci. 2013, DOI: 1
 2013 WILEY-VCH Verlag Gmb
rly View Publication; these are NOT the final pagconfined to the area surrounding the lesion. Furthermore,
it was possible to observe intact neurons in the vicinity of
the lesion.4. Discussion
4.1. PHB-HV Scaffolds Characterization
In order to guide tissue development and organization
into a mature and healthy state, biomaterial scaffolds
must exhibit desirable physical characteristics which
include biocompatibility, adequate mechanical properties,
high porosity, large surface area, adequate pore size,
interconnected porous structures, and biodegradabili-
ty.[19,52,53] Our results demonstrated that freeze-drying0.1002/mabi.201300178
H & Co. KGaA, Weinheim www.MaterialsViews.com
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Figure 6. Direct contact assays with mesenchymal-like stem cells (MSCs) from distinct sources (HUCPVCs, BM-MSCs, and ASCs). Cells were
seeded (50 000 cells per scaffold) and grown up to 7 d. A–D) Representative fluorescence images showing a central area of scaffolds seeded
with MSCs demonstrating that all distinct cell-types were able to adhere, maintain their viability and proliferate throughout the scaffolds
structure during culture period. Nucleus stained in blue (DAPI) and F-actin filaments stained in red (phalloidin). The scale bar indicates
100mm. E) ELISA BrdU data unveiling an increase in the amount of proliferating cells between days 2 and 7 registered for all cell-types.
HUCPVCs proved to be already well established by the 2nd day in culture. O.D. read at 370nm/492nm. F) Total dsDNA quantification data
revealing a significant increase on dsDNA content between days 2 and 7 also observed for all MSCs, being the greatest increase registered
for HUCPVCs. G) MTS test results showing an increase in all MSCs metabolic activity over time, especially for ASCs. O.D. read at 490nm.
(p<0.05, p<0.01, p<0.001; two-way ANOVA, n¼ 3, mean SD).
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scaffolds based on PHB-HV polymer that revealed an
interconnected network of open pores exhibiting
arbitrary shapes, sizes, and directions as previously
reportedbySultanaandWang.[39]Moreover, thedeveloped
scaffolds present high porosity, large pore sizes, and
anisotropic characteristics which influence its mechanical
behavior.
The results herein presented also showed that the
developed scaffolds exhibit laminar pores with some
degree of alignment on its cross-section direction. In
the freeze-drying process, the polymeric solution is frozen
allowing to create an interpenetrating network of ice
crystal that are further removed by sublimation. The
scaffolds herein described were previously prepared in a
petri dish with 90mm 15mm and just further cut inMacromol. Biosci. 2013, DOI:
 2013 WILEY-VCH Verlag Gmwww.MaterialsViews.com
Early View Publication; these are NOsmaller cylindrical pieces (4mm in diameter and 5mm in
height). The introduction of a unidirectional temperature
gradient—resulting from the high ratio between diameter
andheight of the frozen sample—during the freezingphase
induced the formation of laminar pores in the direction of
this gradient.
Though, this was not enough to promote the aligned
guidanceof tissuedepositionwithin thescaffolds structure,
this may be possible in future developments by using the
methodology recently described by Davidenko et al.[54]
Additionally, a reported rough estimation of modulus
values for human spinal cord tissue was 1.02–
1.37MPa,[55,56] and 0.0288MPa for the adult rat spinal
cord.[53] Comparing these modulus values to the ones
obtained for the PHB-HV scaffolds (0.7–0.9MPa in the wet
state), it is possible to assert that from a biomechanical10.1002/mabi.201300178
bH & Co. KGaA, Weinheim 11
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Figure 7. Direct contact assays with OECs. Cells were seeded (200 000 cells per scaffold) and grown up to 14 d. Representative fluorescence
images showing a central area of scaffolds seededwith OECs cultures showing that these cells were able to adhere, maintain their viability,
and proliferate throughout the scaffolds structure after A) 2 d, B) 7 d, and C) 14 d in culture. Nucleus stained in blue (DAPI) and F-actin
filaments stained in red (phalloidin). The scale bar indicates 100mm. D) ELISA BrdU data demonstrating a statistically significant increase in
the amount of proliferating cells between days 2 and 7 in culture followed by its significant decrease between days 7 and 14. O.D. read at
370nm/492nm. E) Total dsDNA quantification data revealing maintenance of the total dsDNA content over time. F) MTS test results
showing maintenance of cells metabolic activity over time. O.D. read at 490nm. (p<0.05, p<0.001; one-way ANOVA, n¼4,
mean SD).
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SCI treatment in humans.
In vitro cytotoxicity assessments allowed the evaluation
of the potential toxic effect of biomaterials on cells.[57]
These are commonly performed using cell lines. However,
the genetic instability and alteration in growth character-
istics (anchorage independence, loss of contact inhibition,
and density limitation of growth) that is often observed in
these types of cell cultures limits the extrapolation of in
vitro data to the in vivo conditions.[58] Primary cultures
on the other hand, in addition to its biological significance,
are capable of maintaining their tissue specific markers
and retain their special function which allows a more
reliable extrapolation between the in vitro data and
in vivo conditions.[59] Considering the aim of these
structures, we found critical to perform the same assess-
ment using CNS-derived primary cell cultures in order to
ascertain the toxic effect that the developed scaffolds could
exhibit over these cells. Our results clearly demonstrated
that the degradation products of the PHB-HV scaffolds do
not affect the metabolic activity of hippocampal-derivedMacromol. Biosci. 2013, DOI: 1
 2013 WILEY-VCH Verlag Gmb
rly View Publication; these are NOT the final pagcells. For all time points there were no significant differ-
ences between MTS metabolization by the positive control
cells and the same reduction performed by the cells from
the PHB-HV extract. On the other hand, the results of the
negative controls clearly evidence a cytotoxic effect over
the cells. Therefore, these results were supportive of a lack
of cytotoxic effect of these structures.4.2. Direct Contact Assays
Neuroregeneration after SCI requires axonal outgrowth
of existing and new axons along with their myelination.
In this sense, to be considered suitable for SCI repair
PHB-HV scaffolds must be able to support the growth of
CNS-derived cells (neurons and glial cells) in its structure.
For this purpose direct contact assays were performed
to evaluate and predict the interaction between CNS-
derived cells (neurons and gial cells) and PHB-HV scaffolds.
The data obtained concerning cell proliferation in hippo-
campal-derived primary cell cultures showed that over
time there was a continuous decrease in the amount of0.1002/mabi.201300178
H & Co. KGaA, Weinheim www.MaterialsViews.com
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Figure 8. In vivo tissue response to PHB-HV 3D scaffolds subcutaneous implantation. Histological sections were stained with H&E. After
A,B) 1 week, C,D) 4 weeks, and E,F) 12 weeks of subcutaneous implantation, the tested PHB-HV 3D scaffolds were well integrated within the
surrounding tissue with minimal inflammatory response. (FT: fibrous tissue; M: muscle; S: PHB-HV scaffolds infiltrated by cells; V: blood
vessels.)
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between the 2nd and 14th day) in culture. These results
may be explained by the presence of neural progenitor
cells[60] or astrocytes, which as described before are also
present in this culture systems.[61] This explanation may
also justify the slight increase in the amount of dsDNA
contained in the scaffolds registered between the 2nd and
7th day in culture (Figure 4e). Moreover, the statistically
significant decrease in the amount of dsDNA observed
between the 7th and 14th day in culture could be related to
cell confluence in the scaffolds that may have led to
cell death and subsequent DNA fragmentation.[43] These
observations are supported by the immunocytochemistry
results which showed that during the three periods in
culture, these cells were able to adhere to the scaffolds
surface,maintain their viability andproliferate throughout
the scaffold in an apparently uniform manner, over time.
However, between the 7th and 14th day in culture therewas
a decrease in specific staining (GFAP andMAP2) supportingMacromol. Biosci. 2013, DOI:
 2013 WILEY-VCH Verlag Gmwww.MaterialsViews.com
Early View Publication; these are NOthe hypothesis of death mediated by cell confluence.
Concerning the metabolic activity of these cells, MTS test
results showed a progressive increase in their metabolic
activity that proved to be statistically significant between
both 2nd–7th day and 2nd–14th day in culture. Additionally,
contrary to what was stated by Capasso[44] these experi-
ments demonstrate that the values obtained for the
MTS test (or similar tests) do not always correlate with
the totalnumberof livingcells. Thereforeonemustconsider
that MTS requires adjuvant cell analyses techniques to
evaluate cell viability.
Regarding primary cultures of cortical glial cells, the
progressive decrease in the amount of proliferating cells
(BrdU) can be explained by an increase in the total number
of cells over time that lead to a reduction of the surface area
available for the expansion of other migrating cells,
thus causing a decrease in the amount of cells that were
proliferating. This observation is supported by the dsDNA
quantification which showed a continuous increase in the10.1002/mabi.201300178
bH & Co. KGaA, Weinheim 13
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Figure 9. In vivo tissue response to PHB-HV 3D scaffolds implantation in a hemisection ratmodel of SCI. A) Left hindlimb locomotor function
recovery evaluation through BBB test. The data revealed no statistical significant differences between the left hindlimb function of control
and PHB-HV groups throughout the testing period. Histological sections of the coronal median cord subdivision were stained with H&E.
After 4weeks, the control group (B) revealed a higher peripheral tissue infiltrationwhen compared to animals inwhich PHB-HV scaffoldwas
implanted following spinal cord injury (C).
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the immunocytochemistry results revealed that during
the three periods in culture, glial cells were also able to
adhere to the scaffold surface, to maintain their viability
and to proliferate throughout the length of the scaffold.
Additionally, this set of data unveils the ability of these
scaffolds to support the in vitro culture of CNS-derived cells
attesting its biocompatibility with these cell types.
MSCs have the potential for self-renewal, multipotency,
migratory behavior to areas of damage and inflammation,
exhibit site-dependent differentiation in response to
environmental signals, and the ability to exert paracrine
effects on other cells that include immunomodulation,
trophic, anti-scarring, and chemoattractant effects.[62,63]
Moreover, it has been suggested that MSCs secretomemay
play a role in potentiating neural progenitors proliferation,
as well as neuronal survival/differentiation.[46,64–66] In
this sense, the strategy that we propose concerns the
combination of PHB-HV-based scaffolds with MSCs inMacromol. Biosci. 2013, DOI: 1
 2013 WILEY-VCH Verlag Gmb
rly View Publication; these are NOT the final pagorder to overcome some of the barriers to regeneration that
arise from an SCI. Our results revealed not only the ability
of the studied MSCs to adhere, maintain their viability and
proliferate within the scaffolds structure, but also pointed
out the higher proliferative potential of HUCPVCs over
BM-MSCs. These observations are supported by the results
obtained by Baksh et al.[67] in a study where the authors
compared the proliferative and multilineage differentia-
tion potential of HUCPVCs and BM-MSCs. Furthermore,
our study also showed that ASCs demonstrated a higher
proliferative potential when compared with BM-MSCs,
being this result supported by the observations described
by Kern et al.[68] in their comparative analysis of BM-MSCs,
UCB-MSCs (umbilical cord blood mesenchymal-like stem
cells) and ASCs.Moreover, our experiments pointed toward
a higher proliferative potential of HUCPVCs comparatively
to ASCs. Lastly, these data revealed the ability of these
scaffolds to support the in vitro culture of HUCPVCs, BM-
MSCs, and ASCs demonstrating its biocompatibility with0.1002/mabi.201300178
H & Co. KGaA, Weinheim www.MaterialsViews.com
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stem cells to the injury site.
OECs derived from the olfactory bulb are claimed to be
suitable candidates for cell-mediated repair following SCI
due to their reported ability to promote axonal regenera-
tion, remyelination, migrate within the CNS and coexist in
anastrocyte-richenvironmentand therefore fully integrate
withina lesion,[69] aswell as topromote functional recovery
following various types of SCI.[70–76] Our results demon-
strated that OECs were also able to adhere to the scaffolds
structure, maintaining their viability and proliferation
throughout the its scaffolds structure. However, the
analysis of their proliferation profile reveals different
results regarding the ELISA BrdU assay and the total dsDNA
quantification revealing an increase in the amount of cells
that were proliferating in the 24h prior to the ELISA BrdU
assay between the 2nd and 7th day in culture, accompanied
by the maintenance of the total amount of dsDNA present
within the scaffolds in the same period. This observation
suggests that although cells did proliferate over time,
some of them may have undergone cell death in an
extent that somehow prevailed over cell proliferation.
Furthermore, maintenance of the total amount of dsDNA
seems to be accompanied bymaintenance of themetabolic
activity throughout time.
These data attests, once more, the biocompatibility of
PHB-HV scaffolds and shows the versatility of these
structures as carriers for delivering different cell popula-
tions relevant for SCI regeneration.4.3. Histocompatibility of PHB-HV Scaffolds
Implantable biomaterials are in direct and sustained
contact with the tissues and some of them degrade in situ.
Therefore, both the material itself and its degradation
products must be devoid of toxicity.[77] As a preliminary
assessment of PHB-HV scaffolds histocompatibility, we
implanted the scaffolds subcutaneously in Wistar rats
and extirpated them after 1, 4, and 12 weeks. Our results
showed that the scaffoldswerewell tolerated by the tissue.
After the initial acute inflammation, no abscess formation
or tissue necrosis was observed in tissues adjacent to the
implanted scaffolds. Moreover, although we observed the
depositionofa thin layerof connective tissueencapsulating
the scaffolds which vanished over time, this does not
attest the non-biocompatibility of these structures and can
be considered as a normal response.[78] According to Mikos
et al.[79] even in the case of a material compatible with the
host tissue, the restitution of normal tissue structure
usually observed following an implantation and wound
healing does not trail the normal pathway. Additionally,
Fournier et al.[77] stated that the body reaction to nearly all
materials considered biocompatible in their application
is similar, involving their engulfment in an avascularMacromol. Biosci. 2013, DOI:
 2013 WILEY-VCH Verlag Gmwww.MaterialsViews.com
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TE/Cell-based combinatorial approach that we propose,
the fibrous capsule surrounding the scaffolds is also an
important factor since it influences cell viability: the more
blood vessels it contains, the more nutrients reach cells,
andbetter is the systemicdeliveryof themolecules secreted
by them.[80] Additionally, the apparent reduction of the
scaffolds structure volume observed at the 12 weeks’ time
point is probably related with the in vivo degradation
rate of the scaffolds. In a recent study, Sultana and Khan[81]
claim that the nonspecific esterase and lysozyme enzymes
secreted by the immune system cells catalyze the faster in
vivo degradation of PHB-HV when compared with its in
vitro hydrolysis rate at the same temperature and pH.
Moreover, it hasbeen reported thatpolyhydroxyalkanoates
(PHAs) undergo surface erosion.[82] Therefore, a detailed
observation of the scaffolds structure shape at the referred
time point suggests that the degradation process had a
greater impact on the scaffolds surface leading to a
reduction on the scaffolds structure volume.
The in vivo histocompatibility evaluation regarding a
hemisection rat model of SCI revealed that the tissue
damage extension between control and PHB-HV groups
was similar. In the PHB-HV group the deleterious effects of
the injury seemed to be confined to the primary lesion,
evidencing a reduced peripheral tissue infiltration when
compared to the control group observations. This evidence
suggests that the PHB-HV scaffold was possibly acting as a
physical barrier that isolated the peripheral inflammatory
process from the one occurring within the nervous tissue.
Therefore, since the results herein presented concern a
4 weeks period assessment one can expect that at a longer
term, the presence of PHB-HV scaffolds could be important
to restrain the deleterious effects mediated by the
peripheral inflammatory response over the nervous tissue
regeneration process. Furthermore, the inflammation
observed on the PHB-HV group was decreased when
compared to the one observed for the subcutaneous
implants. Nevertheless this inflammatory response did
not seem to have a negative impact in the left hindlimb
locomotor function recovery as demonstrated by the BBB
test results. Additionally, as the strategy we propose
involves the combination of the developed PHB-HV
scaffolds with MSCs to assist the SCI regeneration process,
improved outcomes can be expected namely due to the
immunomodelatory and neuroprotective character of
these cells.5. Conclusion
The present study explored freeze-drying, as a processing
methodology, for the production of scaffolds based on
PHB-HV polymer. The scaffolds obtained revealed an10.1002/mabi.201300178
bH & Co. KGaA, Weinheim 15
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REainterconnected network of open pores with high porosity,
large pore sizes, and anisotropic characteristics which
positively influence its mechanical behavior. Furthermore,
the cytotoxicity assessment unveiled the lack of a cytotoxic
effect of these scaffolds over hippocampus derived primary
cell cultures. Direct contact assays revealed the ability of
these structures to support the in vitro culture of CNS-
derived cells and distinct types of MSCs (HUCPVCs, BM-
MSCs, and ASCs) attesting both its biocompatibility and
their potential as carriers for delivering MSCs to the injury
site. Lastly, the histocompatibility studies showed that
PHB-HV 3D scaffolds were well tolerated by the host tissue
revealingvascularizationwithinthescaffoldsstructureand
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